Statins, Rho GTPases and KLF2: New mechanistic insight into liver fibrosis and portal hypertension

Gut

Volumn 64, Issue 9, 2015, Pages 1349-1350

  Trebicka, Jonel ^a   Schierwagen, Robert ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KRUPPEL LIKE FACTOR 2; NITRIC OXIDE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN; KRUPPEL LIKE FACTOR;

DRUG ACTIVITY; DRUG EFFICACY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; GAIN OF FUNCTION MUTATION; HUMAN; INTRAHEPATIC RESISTANCE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER SINUSOIDAL ENDOTHELIAL CELL; LOSS OF FUNCTION MUTATION; NONHUMAN; NOTE; PHENOTYPE; PLEIOTROPY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; STELLATE CELL; ANIMAL; GENETICS; MALE; METABOLISM;

ANIMALS; HEPATIC STELLATE CELLS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LIVER CIRRHOSIS; MALE; SIMVASTATIN;

EID: 84941265711     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308800     Document Type: Note

References (16)

1. Pastori D, Polimeni L, Baratta F, et al. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 2015;47:4-11.
2. Argo CK, Loria P, Caldwell SH, et al. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 2008;48:662-9.
3. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009;203: 325-30.
4. Marrone G, Maeso-Diaz R, Garcia-Cardena G, et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut 2015;64:1434-43.
5. Simon TG, King LY, Zheng H, et al. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol 2015;62:18-23.
6. Zafra C, Abraldes JG, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004;126:749-55.
7. Abraldes JG, Albillos A, Banares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009;136:1651-8.
8. Trebicka J, Hennenberg M, Laleman W, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007;46:242-53.
9. Abraldes JG, Rodriguez-Vilarrupla A, Graupera M, et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol 2007;46:1040-6.
10. Gracia-Sancho J, Russo L, Garcia-Caldero H, et al. Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver. Gut 2011;60:517-24.
11. Trebicka J, Hennenberg M, Odenthal M, et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 2010;53: 702-12.
12. Klein S, Klosel J, Schierwagen R, et al. Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Lab Invest 2012;92:1440-50.
13. Marrone G, Russo L, Rosado E, et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J Hepatol 2013;58:98-103.
14. Moreno M, Ramalho LN, Sancho-Bru P, et al. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. Am J Physiol Gastrointest Liver Physiol 2009;296:G147-56.
15. Klein S, Van Beuge MM, Granzow M, et al. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. J Hepatol 2012;57:1220-7.
16. Granzow M, Schierwagen R, Klein S, et al. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology 2014;60:334-48.